About EpiBiome
EpiBiome is a company based in San Francisco (United States) founded in 2013 was acquired by Locus Biosciences in July 2018. EpiBiome has raised $6 million across 6 funding rounds from investors including Illumina, SVB and ARE. EpiBiome operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Amyris, Chimerix and Syngenta, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6 M (USD)
in 6 rounds
-
Latest Funding Round
$200 K (USD), Grant
Jun 01, 2017
-
Investors
Illumina
& 10 more
-
Employee Count
Not available
-
Acquired by
Locus Biosciences
(Jul 17, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of EpiBiome
EpiBiome has successfully raised a total of $6M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $200 thousand completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EpiBiome
EpiBiome has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Illumina, SVB and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startups are accelerated by Stanford-backed program in Palo Alto.
|
Locked | Locked | Locked | |
|
Early-stage ventures are funded by the investment firm.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for EpiBiome
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EpiBiome
Investment portfolio details for EpiBiome
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EpiBiome
Detailed financials for EpiBiome
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epibiome Comparisons
Peer comparison for EpiBiome
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EpiBiome
EpiBiome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Amyris, Chimerix and Syngenta, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of EpiBiome
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epibiome
Complete news archive for EpiBiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EpiBiome
EpiBiome was founded in 2013 and raised its 1st funding round 1 year after it was founded.
EpiBiome is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
EpiBiome is a funded company, having raised a total of $6M across 6 funding rounds to date.
EpiBiome was founded in 2013 and is headquartered in San Francisco, United States. Antibiotics and phage-based therapeutics are developed by the company for applications in agriculture and human health. Large-scale automation, bioinformatics, and algorithmic methods are employed to create targeted treatments against pathogens, including those resistant to conventional antibiotics. Operations focus on precision in eliminating bacterial threats without broad-spectrum effects.
EpiBiome's top competitors include Moderna, Syngenta and Adaptive Biotechnologies.
EpiBiome has 11 investors. Key investors include Illumina, SVB, ARE, Locus Biosciences, and Gates Foundation.